-
Mashup Score: 5
A new ASCO guideline provides recommendations on the use of systemic therapy for patients with stage I to III anal squamous cell carcinoma, informed by 2 phase 3 randomized controlled trials, RTOG 98-11 and ACT II, as well as retrospective and prospective cohort studies. However, there remains a growing need in the face of rising mortality and incidence for further research into systemic therapy options for this disease state.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9Podcast: What Challenges Will Oncologists Face in 2025? - 7 day(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrYukselUrun: What Challenges Will Oncologists Face in 2025? @ASCO @n8pennell https://t.co/UqviZEUCag https://t.co/K1AuaLOAcR
-
-
Mashup Score: 9Podcast: What Challenges Will Oncologists Face in 2025? - 7 day(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrYukselUrun: What Challenges Will Oncologists Face in 2025? @ASCO @n8pennell https://t.co/UqviZEUCag https://t.co/K1AuaLOAcR
-
-
Mashup Score: 5Podcast: What Challenges Will Oncologists Face in 2025? - 7 day(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Oncologists2Tweet-
Interesting Tallis and thoughts from Nathan Pennell and Sweeteham @n8pennell Podcast: What Challenges Will Oncologists Face in 2025? https://t.co/01gVKi69Hn
-
-
Mashup Score: 2Isatuximab + RVd Improves MRD Negativity, PFS in Patients With Transplant-Eligible, Newly Diagnosed Multiple Myeloma - 9 day(s) ago
Isatuximab is approved to treat disease in patients who are transplant ineligible with newly diagnosed multiple myeloma (MM), but results from a new study show that, when added to another chemotherapy combination, there are also benefits for patients with transplant-eligible, newly diagnosed MM, regardless of subsequent maintenance therapy
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
#ASH24 news: GMMG-HD7 trial showed 66.2% of pts w/ transplant-eligible, newly diagnosed #MultipleMyeloma receiving Isa-RVd achieved MRD negativity posttransplant compared w/ 47.7% on RVd alone: https://t.co/PSD2bg2IcV @JCO_ASCO @ASH_hematology @EliasKarlMai #ASCODailyNews #mmsm https://t.co/tz9c2zv702
-
-
Mashup Score: 66
Considerations for a multidisciplinary discussion about treatment for patients with lymph node involvement from MIBC are multifold, including radical cystectomy versus bladder preservation, novel neoadjuvant therapies, and side effect management. However, recent and ongoing clinical trials have provided potential new options for this patient population.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Bladder Preservation vs Radical Cystectomy in Locally Advanced Muscle-Invasive Bladder Cancer: Selecting Treatment for Patients in an Evolving Therapy Landscape @ASCO https://t.co/vRLCrbfbev
-
-
Mashup Score: 13Podcast: What Challenges Will Oncologists Face in 2025? - 14 day(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
🔮@n8pennell of @ClevelandClinic & Dr. John Sweetenham discuss the top challenges oncologists will face in 2025 + technology's potential to truly improve patient outcomes on the latest episode of the #ASCODailyNews Podcast: https://t.co/oDjFFXd0mc #OncTwitter https://t.co/cbnlKgAgR4
-
-
Mashup Score: 9Understanding and Integrating Emerging Targets Into Treatment Decision-Making for Metastatic CRC - 15 day(s) ago
The landscape of metastatic colorectal cancer (CRC) treatment is rapidly evolving, with the development of new therapeutic strategies targeting several molecular drivers of CRC progression, including HER2, KRAS, RET, and NTRK. A broader adoption of comprehensive genomic profiling through next-generation sequencing and liquid biopsy will be paramount to advance our understanding of mechanisms of resistance and disease progression.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
The landscape of metastatic CRC treatment is evolving w/ the development of new therapeutic strategies targeting molecular drivers of CRC progression. @jaypsv & @GillSharlene examine the significance of these emerging targets for #ASCODailyNews: https://t.co/GU7L0iQfMv #crcsm https://t.co/KsbLAI6eYo
-
-
Mashup Score: 29
Colorectal cancer (CRC) is the leading cause of cancer-related death among men aged 20 to 39, with a similar trend is seen among young women. Multidisciplinary care is particularly critical for patients with early-onset CRC because of several nuances in their care and should include various disciplines—from clinical care teams to social workers and patient advocacy—to offer well-rounded and patient-focused care.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
✳️Proud of my mentees @MeghanaSinghMD and Dr Dulak who put this #ASCODailyNews editorial together in which we provided insights on sobering facts of young onset CRC in the U.S. ‼️ @ASCO Here are some important points👇 https://t.co/cDRVrla8He
-
-
Mashup Score: 2Uptake of Aspirin as Lynch Syndrome Chemoprevention Remains Low. What Oncologists Need to Know to Support Patients - 26 day(s) ago
Only about one-third of patients with Lynch syndrome are using aspirin or nonsteroidal anti-inflammatory agents as a form of chemoprevention, according to a new study published in JCO Precision Oncology.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Only about 1/3 of patients w/ #LynchSyndrome are using aspirin/NSAIDs as a form of chemoprevention, according to a recent study published in @JCOPO_ASCO. #ASCODailyNews covers the study & discusses what oncologists need to know to support patients: https://t.co/Y9ajkWt9UF https://t.co/mwz6cpUYpf
-
For more on this new guideline, read an in-depth analysis from #ASCODailyNews featuring insights from Expert Panel co-chair @VanMorrisMD of @MDAndersonNews: https://t.co/1bHQMYkWxp https://t.co/2ygpyY2Lv0